Regeneron Pharmaceuticals to Replace MetroPCS in S&P 500

Regeneron Pharmaceuticals Inc., maker of the eye medicine Eylea, will replace MetroPCS Communications Inc. in the Standard & Poor’s 500 Index, S&P said in a statement today.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.